News coverage about Marinus Pharmaceuticals (NASDAQ:MRNS) has trended somewhat positive this week, AlphaOne reports. The research firm, a division of Accern, rates the sentiment of news coverage by monitoring more than twenty million news and blog sources. AlphaOne ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Marinus Pharmaceuticals earned a media sentiment score of 0.13 on AlphaOne’s scale. AlphaOne also gave news stories about the biopharmaceutical company an impact score of 12 out of 100, indicating that recent news coverage is very unlikely to have an effect on the company’s share price in the near future.
Here are some of the news headlines that may have effected AlphaOne’s rankings:
- Marinus Pharma (MRNS) to Present Ganaxolone DATA at AAN – StreetInsider.com (streetinsider.com)
- Marinus to present Ganaxolone DATA at American academy of neurology annual meeting (finance.yahoo.com)
- Marinus Pharmaceuticals Inc MRNS Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (bioportfolio.com)
Separately, Zacks Investment Research upgraded shares of Marinus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 target price for the company in a research note on Friday, March 17th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $2.25.
Shares of Marinus Pharmaceuticals (NASDAQ:MRNS) traded down 1.37% during midday trading on Friday, reaching $1.44. 86,315 shares of the company’s stock traded hands. The stock’s market cap is $31.02 million. Marinus Pharmaceuticals has a 52-week low of $0.82 and a 52-week high of $6.45. The stock has a 50 day moving average of $1.51 and a 200-day moving average of $1.28.
Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its quarterly earnings data on Monday, March 13th. The biopharmaceutical company reported ($0.31) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.33) by $0.02. On average, equities research analysts expect that Marinus Pharmaceuticals will post ($1.05) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Marinus Pharmaceuticals (MRNS) Earns Media Sentiment Score of 0.13” was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.chaffeybreeze.com/2017/04/21/marinus-pharmaceuticals-mrns-given-daily-media-sentiment-score-of-0-13-updated.html.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
Receive News & Ratings for Marinus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.